GVR Report cover Retinal Vein Occlusion Treatment Market Size, Share, & Trends Report

Retinal Vein Occlusion Treatment Market Size, Share, & Trends Analysis Report By Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion), By Treatment Type, By End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453513
  • Number of Pages: 0
  • Format: Electronic (PDF)

Retinal Vein Occlusion (RVO) is a condition where blockage of central and branch retinal veins that are important for the supply of blood to the center for pumping and purification. Vein blockage causes vision loss. Several factors have been identified as being associated with RVO conditions, including hypertension, cardiovascular diseases, and glaucoma. It can also cause ischemia, retinal traction, macular edema, and neurovascular complications. The diagnosis of the disease can be done by using optical coherence tomography, fluorescein angiography, and laboratory tests for secondary conditions.

The increasing prevalence of atherosclerosis and diabetes is expected to drive market growth. According to the International Diabetes Federation (IDF), around 537 million adult population suffered from diabetes in 2021 and this number is projected to reach 643 million by 2030 and 783 million by 2045. Thus, increasing the prevalence of secondary conditions may increase the prevalence of RVO and support market growth.

Currently, no treatment is available to reverse retinal vein occlusions. However, there are several medical therapies available to limit complications from the RVO. Some of these therapies include anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy. The anti-VEGF injection therapy is considered a first-line treatment option for macular edema patients with either BRVO or CRVO.

Significant improvements have been demonstrated in macular edema patients who are on anti-VEGF therapy. Corticosteroids such as dexamethasone implant (OZURDEX) are considered second-line therapy for patients with chronic macular edema. Bevacizumab is also used as an off-label for the treatment of patients with neovascularization and macular edema in BRVO and CRVO.

Furthermore, increasing approval of medicines for the treatment of patients with RVO positively contributes to market growth. For instance, in September 2021, the Food and Drug Administration (FDA) approved the first biosimilar drug Byooviz (ranibizumab-nuna) developed by Samsung Bioepis, for the treatment of patients with macular degeneration disease and other eye conditions including RVO. This approval is expected to boost market growth.

However, the high cost associated with retinal occlusion therapy treatment limits the prescription of drugs and restrains the market growth. Based on the BMC Ophthalmology study 2021, treatment with ranibizumab for BRVO and CRVO patients costs around USD 449.17 and USD 454.75 per quality-adjusted life years (QALY) in China. Thus, the introduction of the new product with high safety & efficacy and low cost is anticipated to drive market growth.



Disease Type

Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)


Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, And Others


Hospital & Clinics, Research and Academics, Others


North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA)


Major companies operating in the retinal vein occlusion market include Novartis AG, Bosch Healthcare Solutions GmbH, Bayer AG, Bayer AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and Samsung Bioepis.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon